Krebs Biochemicals: Certificate under SEBI Reg. 74(5) for Q4FY26
Krebs Biochemicals & Industries Limited submitted a certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate, received from RTA KFIN Technologies, confirms dematerialization/rematerialization details were furnished to stock exchanges.
This is a standard regulatory compliance filing, which is a routine activity for listed companies. It does not involve any significant new developments, financial results, or strategic changes that would materially impact the company's operations or stock price.
The announcement is a routine compliance filing regarding share dematerialization and does not contain any new financial or business information that would impact the company's sentiment.
Krebs Biochemicals and Industries Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate pertains to the quarter ended March 31, 2026.
The company has enclosed a copy of the certificates received from KFIN Technologies Limited, the Registrar and Share Transfer Agent. These certificates confirm that details of securities dematerialized/rematerialized during the quarter have been furnished to all the stock exchanges where the company's shares are listed.
The certificates were issued by KFIN Technologies Limited on April 1, 2026, and were submitted to the company on April 7, 2026, for further submission to BSE Limited and the National Stock Exchange of India Ltd.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.